

U. M. Garcia
10/635808

=> dis his


(FILE 'CAOLD' ENTERED AT 10:16:32 ON 28 SEP 2004)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 10:16:44 ON 28 SEP 2004

L1 STR
L2 50 S L1
L3 STR L1
L4 1 S L3
L5 STR L3
L6 308 S L5 FUL

=> d l6 que stat;fil medl,hcapl,embase,biosis;s l6
L5 STR

Ak- NH O Ak Ak N-Ak C=O CH2-C=O
@17 18 @19 20 21 @22 23 @31 32 @33 @34 35



CH2-CH2-CH2 C=O CH-CH C=O O-CH2-CH2 O
@40 41 42 @43 44 @45 46 @47 48 @49 50 @51 52

VAR G1=OH/19/NH2/17/22
VAR G2=31/33-25 34-11/36-25 38-11/40-25 43-11/45-25 47-11/49-25 51-11
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE
L6 308 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED 294255 ITERATIONS
SEARCH TIME: 00.00.27

308 ANSWERS

COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE
ENTRY
166.34
TOTAL
SESSION
690.09

Searched by: Mary Hale 571-272-2507 REM 1D86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-37.10

FILE 'MEDLINE' ENTERED AT 10:33:09 ON 28 SEP 2004

FILE 'HCAPLUS' ENTERED AT 10:33:09 ON 28 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:33:09 ON 28 SEP 2004
 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:33:09 ON 28 SEP 2004
 Copyright (c) 2004 The Thomson Corporation.

L7	44 FILE MEDLINE
L8	174 FILE HCAPLUS
L9	16 FILE EMBASE
L10	0 FILE BIOSIS

TOTAL FOR ALL FILES
 L11 234 L6

=> s l11 and (postlesion? or post lesion? or neurodegenerat? or neurolog? degen? or alzheimer? or dement? or cognitive impairment or neural trauma)


L12	0 FILE MEDLINE
L13	3 FILE HCAPLUS
L14	0 FILE EMBASE
L15	0 FILE BIOSIS

TOTAL FOR ALL FILES
 L16 3 L11 AND (POSTLESION? OR POST LESION? OR NEURODEGENERAT? OR NEUROLOG? DEGEN? OR ALZHEIMER? OR DEMENT? OR COGNITIVE IMPAIRMENT OR NEURAL TRAUMA)

=> d 1-3 cbib abs hitstr

L16 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
 2002:609522 Document No. 137:163818 Tripeptide derivatives for the treatment of **post-lesional** diseases of the nervous system.
 Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques (Tell-Pharm AG, Switz.). Ger. Offen. DE 10105040 A1 20020814, 4 pp.
 (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105040 20010205.

GI



AB The invention discloses the use of cinnamoyl tripeptide derivs. for the

Searched by: Mary Hale 571-272-2507 REM 1D86

treatment of **post-lesional** neuronal diseases. The cinnamoyl tripeptide derivs. are I [X = OH, Cl-5 alkoxy, NH₂, NH(Cl-5 alkyl), N(Cl-5 alkyl)₂; R = (preferably) cinnamoyl; R₁ = group derived from Phe, Tyr, Trp, Pro, Ala, Val, Leu or Ile; R₂ = group derived from Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp and Asn; R₃, R₄ = H, OH, Cl-5 alkyl, Cl-5 alkoxy, provided that R₃ and R₄ are not both OH or Cl-5 alkoxy; R₅ = H, OH, Cl-5 alkyl, Cl-5 alkoxy], or a pharmaceutical acceptable salt thereof.


IT 123910-57-6

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tripeptide derivs. for treatment of **post-lesional** nervous system diseases)

RN 123910-57-6 HCAPLUS


CN L-Prolinamide, N-(1-oxo-3-phenyl-2-propenyl)glycyl-L-phenylalanyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L16 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
2002:591566 Document No. 137:135103 Tripeptide derivatives for treatment of **neurodegenerative** diseases. Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques (Tell-Pharm A.-G., Switz.). Ger. Offen. DE 10105039 A1 20020808, 10 pp. (German). CODEN: GWXXBX.
APPLICATION: DE 2001-10105039 20010205.

GI



AB The invention discloses the use of tripeptide derivs. for treatment of **neurodegenerative** diseases. The tripeptide derivs. are I [X = OH, Cl-5 alkoxy, NH₂, NH(Cl-5 alkyl), N(Cl-5 alkyl)₂; R = (preferably) cinnamoyl; R₁ = group derived from Phe, Tyr, Trp, Pro, Ala, Val, Leu or Ile; R₂ = group derived from Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys,

Pro, Glu, Gln, pGlu, Asp or Asn; R3, R4 = H, OH, C1-5 alkyl, C1-5 alkoxy, provided that R3 and R4 are not both OH or C1-5 alkoxy; R5 = H, OH, C1-5 alkyl, C1-5 alkoxy], or a pharmaceutically compatible salt. Cinnamoyl-Gly-L-Phe-L-Pro-NH2 was tested in an **Alzheimer's** disease model.


IT 123910-57-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tripeptide derivs. for treatment of **neurodegenerative** diseases)

RN 123910-57-6 HCAPLUS

CN L-Prolinamide, N-(1-oxo-3-phenyl-2-propenyl)glycyl-L-phenylalanyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L16 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

1989:633680 Document No. 111:233680 Preparation of tripeptides containing L-proline derivatives as nootropics and pharmaceutical compositions containing them. Fiez-Vandal, Pierre Yves (Inorgan S. A., Switz.). Eur. Pat. Appl. EP 316218 A1 19890517, 18 pp. DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE. (French). CODEN: EPXXDW. APPLICATION: EP 1988-402761 19881103. PRIORITY: FR 1987-15228 19871103.

GI



AB The title compds. [I; R1 = Q; X = CO, YCO, OYCO; Y = alkylene, alkenylene; Z = H, ≥1 CF3, alkyl, alkylenedioxy; R2 = NH2, OH, or a functional derivative thereof; A1, A2 = amino acid residue; B1, B2 = H, Me] and their pharmaceutically acceptable salts, useful as nootropics for treatment of senile **dementia**, **Alzheimer's** disease, Parkinson's disease, schizophrenia, and depression, are prepared via reaction of activated R1-A1-OH with proline derivs. II (R3 = H-A2), obtained by reaction of II (R3 = H) with activated H-A2-OH. N-Cinnamoylglycine (preparation given) was condensed with II.CF3CO2H (R2 = NH2, B1 = B2 = H, R3 = H-Phe) (preparation given) in DMF containing dicyclohexylcarbodiimide and N-methylmorpholine to give I (R1 = cinnamoyl, R2 = NH2, B1 = B2 = H, A1 =

Gly, A2 = Phe) (III). III, administered i.p. or p.o. at 1 mg/kg, was effective in antagonizing scopolamine-induced amnesia in mice.

IT 123910-50-9P 123910-52-1P 123910-53-2P
123910-54-3P 123910-55-4P 123910-56-5P
123910-57-6P 123910-58-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as nootropic)

RN 123910-50-9 HCAPLUS

CN L-Prolinamide, N-[3-(4-fluorophenyl)-1-oxo-2-propenyl]glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 123910-52-1 HCAPLUS

CN L-Prolinamide, N-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 123910-53-2 HCAPLUS

CN L-Prolinamide, N-(1-oxo-3-phenyl-2-propenyl)glycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 123910-54-3 HCAPLUS

CN L-Prolinamide, N-benzoylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123910-55-4 HCAPLUS

CN L-Prolinamide, N-(phenylacetyl)glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 123910-56-5 HCAPLUS

CN L-Proline, 4,4-dimethyl-1-[N-[N-(1-oxo-3-phenyl-2-propenyl)glycyl]-L-phenylalanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 123910-57-6 HCAPLUS
 CN L-Prolinamide, N-(1-oxo-3-phenyl-2-propenyl)glycyl-L-phenylalanyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 123910-58-7 HCAPLUS
 CN L-Prolinamide, N-[3-(1,3-benzodioxol-5-yl)-1-oxo-2-propenyl]glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



=> fil hcapl;e postlesional/ct
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
38.79	728.88

Searched by: Mary Hale 571-272-2507 REM 1D86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.10	-39.20

FILE 'HCAPLUS' ENTERED AT 10:36:25 ON 28 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Sep 2004 VOL 141 ISS 14
 FILE LAST UPDATED: 27 Sep 2004 (20040927/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

E#	FREQUENCY	AT	TERM
--	-----	--	----
E1	0	1	POSTIMPLANTATION/CT
E2	0	2	POSTIMPLANTATION EMBRYO/CT
E3	0	-->	POSTLESIONAL/CT
E4	0	1	POSTMENOPAUSAL/CT
E5	0	2	POSTMENOPAUSAL BONE LOSS/CT
E6	0	2	POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY/CT
E7	0	2	POSTMENOPAUSAL OSTEOPOROSIS/CT
E8	0	2	POSTMENOPAUSE/CT
E9	0	1	POSTMORTEM/CT
E10	0	2	POSTMORTEM HUMAN TISSUE/CT
E11	0	1	POSTNATAL/CT
E12	0	2	POSTNATAL DEPRESSION/CT

=> e neurodegenerative/ct

E#	FREQUENCY	AT	TERM
--	-----	--	----
E1	0	1	NEUROD3/CT
E2	0	2	NEURODEGENERATION/CT
E3	0	1 -->	NEURODEGENERATIVE/CT
E4	0	2	NEURODEGENERATIVE DISEASE/CT
E5	0	2	NEURODEGENERATIVE DISEASES/CT
E6	0	2	NEURODEGENERATIVE DISORDER/CT
E7	0	2	NEURODEGENERATIVE DISORDERS/CT
E8	0	2	NEURODERMATITIS/CT
E9	1		NEURODIA CYCLOPION FLORIDANA/CT
E10	0	2	NEUROECTODERM/CT
E11	0	2	NEUROECTODERM NEOPLASM/CT
E12	0	2	NEUROECTODERM TUMORS/CT

=> e e3+all

E1 0 --> Neurodegenerative/CT
 ***** END *****

=> e alzheimer?/ct

E#	FREQUENCY	AT	TERM
E1	0	1	ALZHEIMER-TYPE/CT
E2	0	2	ALZHEIMER-TYPE SENILE DEMENTIA/CT
E3	0	-->	ALZHEIMER?/CT
E4	0	1	AM/CT
E5	0	2	AM 0.5/CT
E6	0	2	AM 1002/CT
E7	0	2	AM 100L/CT
E8	0	2	AM 111/CT
E9	0	2	AM 2000UP/CT
E10	0	2	AM 6/CT
E11	0	2	AM BLACK/CT
E12	0	2	AM MICROBIAL GENE AND GENETIC ELEMENT/CT

=> e alzheimers/ct

E#	FREQUENCY	AT	TERM
E1	0	1	ALZHEIMER-TYPE/CT
E2	0	2	ALZHEIMER-TYPE SENILE DEMENTIA/CT
E3	0	-->	ALZHEIMERS/CT
E4	0	1	AM/CT
E5	0	2	AM 0.5/CT
E6	0	2	AM 1002/CT
E7	0	2	AM 100L/CT
E8	0	2	AM 111/CT
E9	0	2	AM 2000UP/CT
E10	0	2	AM 6/CT
E11	0	2	AM BLACK/CT
E12	0	2	AM MICROBIAL GENE AND GENETIC ELEMENT/CT

=> e cognitive impairment/ct

E#	FREQUENCY	AT	TERM
E1	0	2	COGNITIVE BEHAVIOR/CT
E2	0	3	COGNITIVE DISORDERS/CT
E3	0	3	--> COGNITIVE IMPAIRMENT/CT
E4	0	3	COGNITIVE MENTAL DISORDER/CT
E5	0	1	COGON/CT
E6	0	2	COGON GRASS/CT
E7	2		COGWHEELS/CT
E8	0	1	COH/CT
E9	0	1	COHAERENS/CT
E10	0	1	COHEN/CT
E11	2	2	COHEN SYNDROME/CT
E12	9		COHEN, ERNST/CT

=> e e3+all

E1	0	-->	Cognitive impairment/CT
E2			USE Cognition (L) disorder/CT
E3			USE Mental disorder (L) cognitive/CT
***** END *****			

=> e neural trauma/ct

E#	FREQUENCY	AT	TERM
E1	0	2	NEURAL TISSUE-SPECIFIC F-ACTIN-BINDING PROTEINS/CT
E2	0	3	NEURAL TRANSPLANT/CT
E3	0	-->	NEURAL TRAUMA/CT
E4	0	2	NEURAL TUBE/CT

E5	0	2	NEURAL TUBE DEFECT/CT
E6	0	2	NEURAL TUBE DEFECTS/CT
E7	0	2	NEURAL TUBE DISEASE/CT
E8	0	2	NEURAL TUBE NERVOUS SYSTEM/CT
E9	0	2	NEURAL TUMORS/CT
E10	0	1	NEURAL-/CT
E11	0	2	NEURAL- AND THYMUS-DERIVED ACTIVATOR FOR ERBB KINASES/ CT
E12	55	2	NEURALGIA/CT

=> fil medl,hcapl,embase,biosis;s l11 and (mental disorder(l)cognitive or cognition(l)disorder)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	7.08	735.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-39.20

FILE 'MEDLINE' ENTERED AT 10:38:28 ON 28 SEP 2004

FILE 'HCAPLUS' ENTERED AT 10:38:28 ON 28 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:38:28 ON 28 SEP 2004
 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:38:28 ON 28 SEP 2004
 Copyright (c) 2004 The Thomson Corporation.

L17	0	FILE MEDLINE
L18	0	FILE HCAPLUS
L19	0	FILE EMBASE
L20	0	FILE BIOSIS

TOTAL FOR ALL FILES

L21	0	L11 AND (MENTAL DISORDER(L) COGNITIVE OR COGNITION(L) DISORDER)
-----	---	---

=> s rapin, j?/au;s witzmann, h?/au;s grumel, j?/au;s gonella, j?/au

L22	114	FILE MEDLINE
L23	166	FILE HCAPLUS
L24	131	FILE EMBASE
L25	149	FILE BIOSIS

TOTAL FOR ALL FILES

L26	560	RAPIN, J?/AU
-----	-----	--------------

L27	3	FILE MEDLINE
L28	134	FILE HCAPLUS
L29	3	FILE EMBASE
L30	3	FILE BIOSIS

TOTAL FOR ALL FILES

L31	143	WITZMANN, H?/AU
-----	-----	-----------------

L32	0	FILE MEDLINE
-----	---	--------------

L33 4 FILE HCAPLUS
L34 2 FILE EMBASE
L35 1 FILE BIOSIS

TOTAL FOR ALL FILES

L36 7 GRUMEL, J?/AU

L37 45 FILE MEDLINE
L38 38 FILE HCAPLUS
L39 29 FILE EMBASE
L40 47 FILE BIOSIS

TOTAL FOR ALL FILES

L41 159 GONELLA, J?/AU

=> s 126 and 131 and 136 and 141

L42 0 FILE MEDLINE
L43 4 FILE HCAPLUS
L44 0 FILE EMBASE
L45 0 FILE BIOSIS

TOTAL FOR ALL FILES

L46 4 L26 AND L31 AND L36 AND L41

=> d 1-4 cbib abs;fil reg

L46 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN


2002:609523 Document No. 137:155181 Synthesis of tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases. **Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques** (Tell-Pharm Ag, Switz.). Ger. Offen. DE 10105041 A1 20020814, 12 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105041 20010205.

AB The invention concerns the use of tripeptide derivs. [e.g., H-Gly-Phe-Pro-NH₂ (I)] for the treatment of neurodegenerative disease, such as Alzheimer's disease. Thus, Boc-Phe-OH [Boc = (CH₃)₃OC(O)] was coupled with TFA.H-Pro-NH₂ to give a dipeptide, which was N-deprotected and converted to its TFA salt for coupling with Boc-Gly-OH; the resulting protected tripeptide was N-deprotected and converted to its HCl salt. The blood-brain partition coeffs. of I and seventeen similar tripeptides were given. The plasma half-life of ¹⁴C-labeled I.HCl was determined in rats (no data). Using a rat model of Alzheimer's disease, results of treatment with I showed retention of learned behavior in a five-day test of pole-climbing at a signal to avoid shock. Examination of subject brains revealed increase dendrite development in the hippocampus.

L46 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:609522 Document No. 137:163818 Tripeptide derivatives for the treatment of post-lesional diseases of the nervous system. **Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques** (Tell-Pharm AG, Switz.). Ger. Offen. DE 10105040 A1 20020814, 4 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105040 20010205.

GI



AB The invention discloses the use of cinnamoyl tripeptide derivs. for the treatment of post-lesional neuronal diseases. The cinnamoyl tripeptide derivs. are I [X = OH, C1-5 alkoxy, NH₂, NH(C1-5 alkyl), N(C1-5 alkyl)₂; R = (preferably) cinnamoyl; R1 = group derived from Phe, Tyr, Trp, Pro, Ala, Val, Leu or Ile; R2 = group derived from Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp and Asn; R3, R4 = H, OH, C1-5 alkyl, C1-5 alkoxy, provided that R3 and R4 are not both OH or C1-5 alkoxy; R5 = H, OH, C1-5 alkyl, C1-5 alkoxy], or a pharmaceutical acceptable salt thereof.

L46 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN


2002:609521 Document No. 137:140781 Synthesis of tripeptides and tripeptide derivatives for the treatment of post lesional diseases of the nervous system.. **Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques** (Tell-Pharm Ag, Switz.). Ger. Offen. DE 10105038 A1 20020814, 10 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105038 20010205.

AB The invention concerns the use of tripeptide derivs. [e.g., H-Gly-Phe-Pro-NH₂ (I)] for the treatment of post lesional diseases of the nervous system. Thus, Boc-Phe-OH [Boc = (CH₃)₃OC(O)] was coupled with TFA.H-Pro-NH₂ to give a dipeptide, which was N-deprotected and converted to its TFA salt for coupling with Boc-Gly-OH; the resulting protected tripeptide was N-deprotected and converted to its HCl salt. The blood-brain partition coeffs. of I and seventeen similar tripeptides were given. The plasma half-life of ¹⁴C-labeled I.HCl was determined in rats (no data). Using an in-vivo dendritic sprouting assay in rats, I was tested for effect on hippocampus septum, and showed growth of up to 2µm, compared to controls.

L46 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:591566 Document No. 137:135103 Tripeptide derivatives for treatment of neurodegenerative diseases. **Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques** (Tell-Pharm A.-G., Switz.). Ger. Offen. DE 10105039 A1 20020808, 10 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105039 20010205.

GI



AB The invention discloses the use of tripeptide derivs. for treatment of neurodegenerative diseases. The tripeptide derivs. are I [X = OH, C1-5 alkoxy, NH₂, NH(C1-5 alkyl), N(C1-5 alkyl)₂; R = (preferably) cinnamoyl; R1 = group derived from Phe, Tyr, Trp, Pro, Ala, Val, Leu or Ile; R2 = group derived from Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp or Asn; R3, R4 = H, OH, C1-5 alkyl, C1-5 alkoxy, provided that R3 and R4 are not both OH or C1-5 alkoxy; R5 = H, OH, C1-5 alkyl, C1-5 alkoxy], or a pharmaceutically compatible salt. Cinnamoyl-Gly-L-Phe-L-Pro-NH₂ was tested in an Alzheimer's disease model.

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	15.01	750.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.80	-42.00

FILE 'REGISTRY' ENTERED AT 10:40:05 ON 28 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1
 DICTIONARY FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=> e "cinnamoyl-glycyl-l-phenylalanyl-l-prolinamide"/cn
E1      1      CINNAMOYL-COA: (R)-PHENYLACTATE COA-TRANSFERASE/CN
E2      1      CINNAMOYL-COENZYME A REDUCTASE/CN
E3      0 --> CINNAMOYL-GLYCYL-L-PHENYLALANYL-L-PROLINAMIDE/CN
E4      1      CINNAMOYLACETALDEHYDE/CN
E5      1      CINNAMOYLACETONE/CN
E6      1      CINNAMOYLACETONITRILE/CN
E7      1      CINNAMOYLAUBUCIN/CN
E8      1      CINNAMOYLAUCUBIN/CN
E9      1      CINNAMOYLCHOLINE/CN
E10     1      CINNAMOYLCHOLINE CHLORIDE/CN
E11     1      CINNAMOYLCOCAINE/CN
E12     1      CINNAMOYLDIAMINOPIPERAZINE/CN

=>
=> e
E13     1      CINNAMOYLECGONINE/CN
E14     1      CINNAMOYLECGONINE METHYL ESTER/CN
```

Searched by: Mary Hale 571-272-2507 REM 1D86

E15	1	CINNAMOYLETHYL METHACRYLATE-DIMETHYLOCTYLAMMONIUM STYRENESULFONATE-METHACRYLIC ACID-TRIS (TRIMETHYLSILOXY) (3- (METHACRYLOYLOXY) PROPYL) SILANE COPOLYMER/CN
E16	1	CINNAMOYLETHYL METHACRYLATE-STYRENE BLOCK COPOLYMER/CN
E17	1	CINNAMOYLFERROCENE/CN
E18	1	CINNAMOYLGLUCOSE-ALCOHOL CINNAMOYLTRANSFERASE/CN
E19	1	CINNAMOYLGLYCINE/CN
E20	1	CINNAMOYLGLYCINE P-NITROPHENYL ESTER/CN
E21	1	CINNAMOYLGRANDIFLORIC ACID/CN
E22	1	CINNAMOYLHYDRAZINE/CN
E23	1	CINNAMOYLHYDROXAMIC ACID/CN
E24	1	CINNAMOYLIIUM/CN

```
=> s cinnamoyl(1)glycyl(1)phenylalanyl(1)prolinamide
      3686 CINNAMOYL
        1 CINNAMOYLS
      3686 CINNAMOYL
          (CINNAMOYL OR CINNAMOYLS)
    492293 GLYCYL
        2 GLYCYLS
    492293 GLYCYL
          (GLYCYL OR GLYCYLS)
    367484 PHENYLALANYL
      21527 PROLINAMIDE
L47      0 CINNAMOYL (L) GLYCYL (L) PHENYLALANYL (L) PROLINAMIDE
```

```
=> e "cinnamoyl-isoleucyl-phenylalanyl-l-proline ethylamide"/cn
E1      1 CINNAMOYL-COA: (R)-PHENYLLACTATE COA-TRANSFERASE/CN
E2      1 CINNAMOYL-COENZYME A REDUCTASE/CN
E3      0 --> CINNAMOYL-ISOLEUCYL-PHENYLALANYL-L-PROLINE ETHYLAMIDE/CN
E4      1 CINNAMOYLACETALDEHYDE/CN
E5      1 CINNAMOYLACETONE/CN
E6      1 CINNAMOYLACETONITRILE/CN
E7      1 CINNAMOYLAUBUCIN/CN
E8      1 CINNAMOYLAUCUBIN/CN
E9      1 CINNAMOYLCHOLINE/CN
E10     1 CINNAMOYLCHOLINE CHLORIDE/CN
E11     1 CINNAMOYLCOCAINE/CN
E12     1 CINNAMOYLDIAMINOPIPERAZINE/CN
```

```
=> s cinnamoyl(1)isoleucyl(1)phenylalanyl(1)proline(1)ethylamide
      3686 CINNAMOYL
        1 CINNAMOYLS
      3686 CINNAMOYL
          (CINNAMOYL OR CINNAMOYLS)
    325112 ISOLEUCYL
    367484 PHENYLALANYL
      85965 PROLINE
        2 PROLINES
      85965 PROLINE
          (PROLINE OR PROLINES)
      621 ETHYLAMIDE
L48      0 CINNAMOYL (L) ISOLEUCYL (L) PHENYLALANYL (L) PROLINE (L) ETHYLAMIDE
```

```
=> e "cinnamoyl-isoleucyl-isoleucyl-prolineamide"/cn
E1      1 CINNAMOYL-COA: (R)-PHENYLLACTATE COA-TRANSFERASE/CN
E2      1 CINNAMOYL-COENZYME A REDUCTASE/CN
E3      0 --> CINNAMOYL-ISOLEUCYL-ISOLEUCYL-PROLINEAMIDE/CN
E4      1 CINNAMOYLACETALDEHYDE/CN
E5      1 CINNAMOYLACETONE/CN
E6      1 CINNAMOYLACETONITRILE/CN
E7      1 CINNAMOYLAUBUCIN/CN
```

E8 1 CINNAMOYL AUCUBIN/CN
 E9 1 CINNAMOYL CHOLINE/CN
 E10 1 CINNAMOYL CHOLINE CHLORIDE/CN
 E11 1 CINNAMOYL COCAINE/CN
 E12 1 CINNAMOYL DIAMINOPIPERAZINE/CN

=> s cinnamoyl(1)isoleucyl(1)isoleucyl(1)prolineamide
 3686 CINNAMOYL
 1 CINNAMOYLS
 3686 CINNAMOYL
 (CINNAMOYL OR CINNAMOYLS)
 325112 ISOLEUCYL
 325112 ISOLEUCYL
 2 PROLINEAMIDE
 L49 0 CINNAMOYL(L) ISOLEUCYL(L) ISOLEUCYL(L) PROLINEAMIDE

=> fil medl,hcap,biosis,embase,wpids		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	59.69	810.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-42.00

FILE 'MEDLINE' ENTERED AT 10:43:03 ON 28 SEP 2004

FILE 'HCAPLUS' ENTERED AT 10:43:03 ON 28 SEP 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:43:03 ON 28 SEP 2004
 Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 10:43:03 ON 28 SEP 2004
 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 10:43:03 ON 28 SEP 2004
 COPYRIGHT (C) 2004 THE THOMSON CORPORATION

=> s cinnamoyl(1)isoleucyl(1)isoleucyl(1)prolineamide
 L50 0 FILE MEDLINE
 L51 0 FILE HCAPLUS
 L52 0 FILE BIOSIS
 L53 0 FILE EMBASE
 L54 0 FILE WPIDS

TOTAL FOR ALL FILES
 L55 0 CINNAMOYL(L) ISOLEUCYL(L) ISOLEUCYL(L) PROLINEAMIDE

=> s cinnamoyl(1)isoleucyl(1)phenylalanyl(1)proline(1)ethylamide
 L56 0 FILE MEDLINE
 L57 0 FILE HCAPLUS
 L58 0 FILE BIOSIS
 L59 0 FILE EMBASE
 L60 0 FILE WPIDS

TOTAL FOR ALL FILES
 L61 0 CINNAMOYL(L) ISOLEUCYL(L) PHENYLALANYL(L) PROLINE(L) ETHYLAMIDE

=> s cinnamoyl(1)glycyl(1)phenylalanyl(1)prolinamide

L62 0 FILE MEDLINE
L63 0 FILE HCAPLUS
L64 0 FILE BIOSIS
L65 0 FILE EMBASE
L66 1 FILE WPIDS

TOTAL FOR ALL FILES

L67 1 CINNAMOYL(L) GLYCYL(L) PHENYLALANYL(L) PROLINAMIDE

=> d

L67 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2002-667977 [72] WPIDS
DNC C2002-187773
TI Use of proline-containing tripeptide for treating neurodegeneration,
useful particularly in early stages of Alzheimer's disease.
DC B02 B03
IN GONELLA, J; GRUMEL, J; RAPIN, J; WITZMANN, H K
PA (TELL-N) TELL-PHARM AG; (NEUR-N) NEUROTOLL AG
CYC 101
PI DE 10105039 A1 20020808 (200272)* 10 A61K038-06
WO 2002062830 A1 20020815 (200272) EN C07K005-08
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
ZW
EP 1358204 A1 20031105 (200377) EN C07K005-08
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR
AU 2002247685 A1 20020819 (200427) C07K005-08
ADT DE 10105039 A1 DE 2001-10105039 20010205; WO 2002062830 A1 WO 2002-EP1181
20020205; EP 1358204 A1 EP 2002-716727 20020205, WO 2002-EP1181 20020205;
AU 2002247685 A1 AU 2002-247685 20020205
FDT EP 1358204 A1 Based on WO 2002062830; AU 2002247685 A1 Based on WO
2002062830
PRAI DE 2001-10105039 20010205
IC ICM A61K038-06; C07K005-08
ICS A61P025-28

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.98	822.64

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-42.00

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 10:43:58 ON 28 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1
DICTIONARY FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1

Searched by: Mary Hale 571-272-2507 REM 1D86

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> del his y

=>